Serum β-hCG as a Biomarker in Pancreatic Neuroendocrine Tumors: Rethinking Single-Analyte Approach
Open Access
Abstract
Despite recent advances, neuroendocrine tumors (NETs) remain a challenging topic, due to their diversity and the lack of suitable biomarkers. Multianalyte assays and the shift to an omics-based approach improve on the conventional single-analyte strategy, albeit with their own drawbacks. We explored the potential of serum β-hCG as a biomarker for NETs and discussed its role in disease monitoring. We recruited 40 patients with non-functioning pancreatic NETs, all with liver metastases. Serum β-hCG concentrations were measured at 3-month intervals over 48 months. We performed a comparative and a repeated measures analysis of β-hCG depending on WHO grade (G1, G2), liver tumor burden (LTB; below 10%, 10–25%), and RECIST 1.1. (stable disease, progressive disease). Patients with progressive disease (p < 0.001), 10–25% LTB (p < 0.001) and WHO Grade 2 (p < 0.001) displayed higher β-hCG concentrations. Throughout the study, β-hCG concentrations consistently increased across the entire cohort. Delta β-hCG during the study period was greater in patients with 10–25% LTB (p < 0.001), progressive disease (p < 0.001), and G2 (p = 0.003). Serum β-hCG correlates with established indicators of malignancy and disease progression in metastatic NETs, supporting further studies as a monitoring and prognostic biomarker. Despite promising results from novel biomarkers, there is still a place for single-analyte assays in NETs.Keywords
Funding Information
- Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu (NMN0000067)
This publication has 37 references indexed in Scilit:
- Overview of the 2022 WHO Classification of Neuroendocrine NeoplasmsEndocrine Pathology, 2022
- Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?Current Oncology Reports, 2021
- Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%?The Oncologist, 2020
- The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumorsAdvances in Medical Sciences, 2020
- Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United StatesJAMA Oncology, 2017
- Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasmsJournal of Endocrinological Investigation, 2014
- Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs)Best Practice & Research Clinical Gastroenterology, 2012
- hCG, five independent moleculesClinica Chimica Acta, 2012
- Detection of β-human chorionic gonadotropin mRNA as a marker for cutaneous malignant melanomaInternational Journal of Cancer, 1996
- The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancerEuropean Journal of Cancer, 1996